These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38448169)

  • 1. [Clinical features and prognostic analysis of checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer].
    Chen RX; Liu XN; Xu Y; Shi YJ; Wang MQ; Shao C; Huang H; Xu K; Wang MZ; Xu ZJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Mar; 47(3):207-213. PubMed ID: 38448169
    [No Abstract]   [Full Text] [Related]  

  • 2. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
    Huang A; Xu Y; Zang X; Wu C; Gao J; Sun X; Xie M; Ma X; Deng H; Song J; Ren F; Pang L; Qian J; Yu Z; Wan S; Chen Y; Pan L; Zhuang G; Liu S; Xue X
    BMC Cancer; 2021 May; 21(1):634. PubMed ID: 34051746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
    Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
    Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease.
    Zeng Z; Qu J; Yao Y; Xu F; Lu S; Zhang P; Yao Y; Li N; Zhou J; Wang Y
    BMC Pulm Med; 2022 Dec; 22(1):458. PubMed ID: 36456932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study.
    Wang H; Zhao Y; Zhang X; Si X; Song P; Xiao Y; Yang X; Song L; Shi J; Zhao H; Zhang L
    Cancer Med; 2021 Jan; 10(1):188-198. PubMed ID: 33211395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
    Pang L; Xie M; Ma X; Huang A; Song J; Yao J; Deng H; Zhang D; Zang X; Ren F; Gao J; Wu C; Wang Y; Zhang X; Bao X; Pan L; Xue X
    BMC Cancer; 2023 Mar; 23(1):203. PubMed ID: 36869304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
    Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
    J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical and chest CT features of immune checkpoint inhibitor-related pneumonitis].
    Zhang Q; Zhao SJ; Wang SH; Tao XL; Wu N
    Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):182-187. PubMed ID: 36781241
    [No Abstract]   [Full Text] [Related]  

  • 9. Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer.
    Moda M; Saito H; Kato T; Usui R; Kondo T; Nakahara Y; Murakami S; Yamamoto K; Yamada K
    Thorac Cancer; 2020 Dec; 11(12):3576-3584. PubMed ID: 33078531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Cancer Patients: A Systemic Review and Meta-Analysis.
    Zhou P; Zhao X; Wang G
    Respiration; 2022; 101(11):1035-1050. PubMed ID: 36108598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of preexisting lung ground glass opacities on CT for predicting checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients.
    Wang X; Zhao J; Mei T; Liu W; Chen X; Wang J; Jiang R; Ye Z; Huang D
    BMC Cancer; 2024 Feb; 24(1):269. PubMed ID: 38408928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predict factors and clinical prognosis value of immune-related pneumonia of receiving PD-1 inhibitor in advanced non-small cell lung cancer: A retrospective study.
    Yang J; Lyu M; Feng X; Liu F; Zeng R; Sun X; Bao Z; Zhou L; Gao B; Ni L; Xiang Y
    Int Immunopharmacol; 2024 Dec; 142(Pt B):113140. PubMed ID: 39312858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management, risk factors and prognostic impact of checkpoint-inhibitor pneumonitis (CIP) in lung cancer - A multicenter observational analysis.
    Frost N; Unger K; Blum TG; Misch D; Kurz S; Lüders H; Olive E; Raspe M; Hilbrandt M; Koch M; Böhmer D; Senger C; Witzenrath M; Grohé C; Bauer T; Modest DP; Kollmeier J
    Lung Cancer; 2023 May; 179():107184. PubMed ID: 37040677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients.
    Zhai X; Zhang J; Tian Y; Li J; Jing W; Guo H; Zhu H
    Cancer Biol Med; 2020 Aug; 17(3):599-611. PubMed ID: 32944393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinguishing immune checkpoint inhibitor-related pneumonitis from radiation pneumonitis by CT radiomics features in non-small cell lung cancer.
    Peiliang Wang MD; Yikun Li MM; Mengyu Zhao MM; Jinming Yu MD; Feifei Teng MD
    Int Immunopharmacol; 2024 Feb; 128():111489. PubMed ID: 38266450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting checkpoint inhibitors pneumonitis in non-small cell lung cancer using a dynamic online hypertension nomogram.
    Jia X; Chu X; Jiang L; Li Y; Zhang Y; Mao Z; Liang T; Du Y; Xu L; Shen Y; Niu G; Meng R; Ni Y; Su C; Guo H
    Lung Cancer; 2022 Aug; 170():74-84. PubMed ID: 35717705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials.
    Lin GF; Xu Y; Lin H; Yang DY; Chen L; Huang LL; Su XS; Xu YX; Zeng YM
    Int Immunopharmacol; 2021 Oct; 99():108011. PubMed ID: 34426108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer.
    Ono K; Ono H; Toi Y; Sugisaka J; Aso M; Saito R; Kawana S; Aiba T; Odaka T; Matsuda S; Saito S; Narumi A; Ogasawara T; Shimizu H; Domeki Y; Terayama K; Kawashima Y; Nakamura A; Yamanda S; Kimura Y; Honda Y; Sugawara S
    Cancer Med; 2021 Jul; 10(14):4796-4804. PubMed ID: 34121358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Meta-analysis.
    Zhang M; Fan Y; Nie L; Wang G; Sun K; Cheng Y
    Chest; 2022 Jun; 161(6):1675-1686. PubMed ID: 35026298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Clinical Analysis of Checkpoint Inhibitor Pneumonitis with Different Severities in Lung Cancer Patients: A Retrospective Study.
    Huang H; Chen R; Xu Y; Fang N; Shao C; Xu K; Wang M
    J Clin Med; 2024 Jan; 13(1):. PubMed ID: 38202262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.